2020 Advisory Committee

Patricia Friend, PhD, APRN-CNS, AOCNS, AGN-BC, has advanced certification in oncology nursing, is board certified in advanced genetics nursing, and is licensed as an APRN-CNS (Clinical Nurse Specialist). Her areas of expertise are oncology and genomics, educational preparation of advanced practice nurses, online education, and interprofessional education and practice. Dr. Friend’s doctoral dissertation work was supported by the American Cancer Society (doctoral scholarship), and her pre-doctoral fellowship (F31) was from the National Cancer Institute. Dr. Friend’s doctoral research—examining the interactions between stress and immune responses in women undergoing diagnostic breast biopsy—was funded by the National Cancer Institute, the Oncology Nursing Foundation, and the Chicago Chapter of the Oncology Nursing Society. Dr. Friend has experience with educational training grants, and she currently leads a team of faculty supported by the NCI-sponsored Interprofessional Education Exchange (iPEX) Project, which is developing interprofessional education in palliative care.

Dr. Friend’s main area of clinical scholarship and research interest is genetics/genomics. She serves on the Genomics Advisory Board for the Oncology Nursing Society, and she is interested in improving the genomic literacy of healthcare educators, students, and clinicians. Dr. Friend has taught a Cancer Genomics course for graduate nursing students for many years.

Jennifer Godden, PharmD, BCOP, is the Co-Director of Oncology Precision Medicine at Advocate Aurora Health Care in Milwaukee, WI. She received her Doctor of Pharmacy degree from the University of Iowa in 2007, graduating with high distinction. Following graduation, Dr. Godden completed a PGY-1 Pharmacy Practice Residency with Aurora Health Care (AHC). She worked at AHC for an additional two as an inpatient clinical pharmacist before becoming AHC’s first PGY-2 Oncology Pharmacy Specialty Resident. After her second residency, Dr. Godden continued to work for AHC as an oncology clinical coordinator for five years before moving into her current position. Dr. Godden is board certified as an oncology pharmacist by the American College of Clinical Pharmacy and is a member of the Hematology Oncology Pharmacy Association and Pharmacy Society of Wisconsin.

Annette S. Kim, MD, PhD, is an Associate Professor of Pathology at Harvard Medical School and a practicing hematopathologist and molecular pathologist at Brigham and Women's Hospital in Boston, MA. She has prior training in synthetic organic chemistry and structural biology, and she spent several years in the pharmaceutical industry before returning to academia. Since returning to clinical practice, Dr. Kim has practiced diagnostic hematopathology and molecular pathology, and she is the Associate Director of the Center for Advanced Molecular Diagnostics, in which role she has directed assay validation and quality assurance.

Dr. Kim has experience implementing, receiving funding for, and publishing on efforts in test utilization management, conducting studies on the cost-effective practice of hematopathology. She has been an active member of the Association of Molecular Pathology, serving as chair of several committees and as a member of the Executive Committee, Strategic Opportunities Committee, and Board. She also serves on the College of American Pathologists Molecular Oncology Committee. Through these societies, Dr. Kim has published key papers on myeloid mutational patterns and the performance of FDA companion diagnostics and laboratory developed assays, including the performance of next-generation sequencing assays.

Edward S. Kim, MD, MBA, FACP, FASCO, is physician-in-chief at City of Hope Orange County and vice physician-in-chief at City of Hope National Medical Center. Dr. Kim joins City of Hope in fulfilling its promise of enhancing local access to cancer breakthroughs by leading its esteemed team of clinicians in Orange County, CA. Dr. Kim's goals for City of Hope are to promote strategic and team-oriented translational research and patient advocacy for greater accessibility and equitability in cancer care.

A U.S. News & World Report "Top Doctor" and clinician world-renowned for his immense oncology experience, Dr. Kim is poised to drive innovation in cancer care and delivery, developing paradigms for translating research into clinical practice and introducing new therapies for the Orange County clinical network and planned Irvine campus. Backed by a distinguished history of pioneering cancer research, Dr. Kim is among the country's foremost experts in molecular prognostication for lung cancer and head and neck cancers. He's served as a principal/co-principal investigator on numerous studies and protocols, and he has authored/co-authored more than 200 published articles, book chapters, and reviews in top-tier journals.

Before joining City of Hope, Dr. Kim was chair of Solid Tumor Oncology and Investigational Therapeutics, the Donald S. Kim Distinguished Chair for Cancer Research, medical director of the Clinical Trials Office at Levine Cancer Institute, and a professor of medicine at the University of North Carolina (UNC) at Chapel Hill. He has held many leadership roles, such as tenured associate professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center. Dr. Kim recently completed his MBA at the UNC Kenan-Flagler Business School.

Kathryn A. Phillips, PhD, is a professor of Health Economics and Health Services Research at the University of California San Francisco. Her expertise is on the implementation of new technologies to improve healthcare. In 2008, she founded the UCSF Center for Translational and Policy Research on Personalized Medicine, an internationally recognized leader in developing objective evidence on value and coverage. Dr. Phillips has published more than 150 journal articles in JAMA, New England Journal of Medicine, Health Affairs, and others; she has led NIH grants for more than 25 years; and she serves on the editorial boards of leading journals, including Health Affairs, Value in Health, and JAMA Internal Medicine. A distinguishing characteristic of Dr. Phillips’ work is the translation of science into policy insights by bringing together the perspectives of insurers, industry, and government. Dr. Phillips has served on national and international scientific advisory committees for the National Academy of Medicine, Food and Drug Administration, President’s Council of Advisors on Science and Technology, GenomeCanada, and others. Dr. Phillips currently serves on GenomeCanada’s board of directors.

Michelle Shiller, DO, AP/CP, MGP, became board certified in Anatomic, Clinical, and Molecular Genetic Pathology following the completion of her residency at Baylor University Medical Center in Dallas, Texas, and her fellowship at The Mayo Clinic in Rochester, Minnesota. Upon completion of her training, Dr. Shiller established a practice with Pathologists Biomedical Laboratories in Dallas, Texas, which services the majority of the Dallas/Ft. Worth Metroplex Baylor Scott and White Hospitals. Dr. Shiller sits on the Quality Committee for the Baylor Sammons Cancer Center; serves as the Assistant Medical Director for Cancer Genetics, primarily focusing on germline cancer predisposition; and is the Co-Assistant Medical Director for the Division of Molecular Medicine and Pathology. Dr. Shiller has also served on the Baylor Medical Board. Dr. Shiller has served on steering committees and advisory boards for multiple entities. She is an active member of the Association for Molecular Pathology, where she has developed a consistent dialogue between molecular pathology and oncology, and she assists with developing the ASCO-sponsored Molecular Tumor Board..